Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Inventage Lab., Inc.
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05620940CT.gov A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects. | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Alcohol Dependence
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ivl4002 (this asset) | Inventage Lab., Inc. | P1 | CC · 43 |
| Naltrexone | Inventage Lab., Inc. | P4 | BBB |
| Acamprosate | Hanyang University Seoul Hospital | P4 | BBB |
| Escitalopram | University of Texas Southwestern Medical Center | P4 | BBB |
| Topiramate | Stanford University | P4 | BB |
| Fluoxetine | New York State Psychiatric Institute | P4 | BB |
| Lamotrigine | Medical University of South Carolina | P4 | BB |
| Quetiapine | University of Texas Southwestern Medical Center | P4 | BB |
| Varenicline | State University of New York - Upstate Medical University | P4 | BB |
+18 more in the Alcohol Dependence cohort
Other indications for ivl4002
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Opiate Dependence | — | P1 | CC · 43 |
| Multiple Sclerosis | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ivl4002 in Alcohol Dependence. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ivl4002-alcohol-dependence
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →